Effectiveness of antiplatelet drugs against experimental non-alcoholic fatty liver disease

Gut

Volumn 57, Issue 11, 2008, Pages 1583-1591

  Fujita, K ^a   Nozaki, Y ^a   Wada, K ^b   Yoneda, M ^a   Endo, H ^a   Takahashi, H ^a   Iwasaki, T ^a   Inamori, M ^a   Abe, Y ^a   Kobayashi, N ^a   Kirikoshi, H ^a   Kubota, K ^a   Saito, S ^a   Nagashima, Y ^a   Nakajima, A ^a  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b OSAKA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; CILOSTAZOL; MITOGEN ACTIVATED PROTEIN KINASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE B; RAF PROTEIN; TICLOPIDINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; LIPID DIET; MALE; NONALCOHOLIC FATTY LIVER; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; RAT; SIGNAL TRANSDUCTION;

ALANINE TRANSAMINASE; ANIMALS; ASPIRIN; CHOLESTEROL; CHOLINE DEFICIENCY; DIETARY FATS; DRUG EVALUATION, PRECLINICAL; FATTY LIVER; HUMANS; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; PLATELET AGGREGATION INHIBITORS; RATS; RATS, INBRED F344; TETRAZOLES; TICLOPIDINE; TREATMENT OUTCOME;

EID: 54049103536     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.2007.144550     Document Type: Article

References (36)

1. el-Hassan AY, Ibrahim EM, Chammas MY, et al. Fatty infiltration of the liver: analysis of prevalence, radiological and clinical findings. Br J Radiol 1992;65:774-8.
2. Farrell GC. Non-alcoholic steatohepatitis: what is it, and why is it important in the Asia-Pacific region? J Gastroenterol Hepatol 2003;18:124-38.
3. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-31.
4. James FW, Day CP. Non-alcoholic steatohepatitis (NASH): a disease of emerging identity and importance. J Hepatol 1998;29:495-501.
5. Sheth SG, Gordon FD, Chopar S. Nonalcoholic steatohepatitis. Ann Intern Med 1997;126:137-45.
6. Deng XQ, Chen LL, Li NX. The expression of SIRT1 in nonalcoholic fatty liver disease induced by high-fat diet in rats. Liver Int 2007;27:708-15.
7. Kawaguchi K, Sakaida I, Tsuchiya M, et al. Pioglitazone prevents hepatic steatosis, fibrosis, and enzyme-altered lesions in rat liver cirrhosis induced by a choline-deficient L-amino acid-defined diet. Biochem Biophys Res Commun 2004:27;315:187-95.
8. Ahn YK, Cho JG, Kang JC, et al. The effects of antiplatelet agents in the prevention of ventricular tachyarrhythmias during acute myocardial ischemia in rats. Jpn Heart J 1999;40:79-86.
9. Ono S, Ashida S, Abiko Y. Hemorheological effect of ticlopidine in the rat. Thrombosis Res 1983;31:549-56.
10. Aoki M, Morishita R, Ogihara T, et al. Inhibition of neointimal formation after balloon injury by cilostazol, accompanied by improvement of endothelial dysfunction and induction of hepatocyte growth factor in rat diabetes model. Diabetologia 2001;44:1034-42.
11. Sahai A, Malladi P, Pan X, et al. Obese and diabetic db/db mice develop marked liver fibrosis in a model of nonalcoholic steatohepatitis: role of short-form leptin receptors and osteopontin. Am J Physiol Gastrointest Liver Physiol 2004;287:1035-43.
12. Kleiner DE, Brunt EM, Sanyal AJ, et al. Design and validation of histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005;41:1313-21.
13. Angulo P, Keach JC, Batts KP, et al. Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis. Hepatology 1999;30:1356-62.
14. Sugimoto R, Enjoji M, Kohjima M, et al. High glucose stimulates hepatic stellate cells to proliferate and to produce collagen through free radical production and activation of mitogen-activated protein kinase. Liver Int 2005;25:1018-26.
15. Yagi K. Simple assay for the level of total lipid peroxides in serum or plasma. Methods Mol Biol 1998;108:101-6.
16. Applied Biosystems. User Bulletin 2 - ABI PRISM 7700 Sequence Detection System. Applied Biosystems, Foster City, California, USA; December 11, 1997 (updated Oct 2001).
17. Marshall SE, Welsh KI. Tumor necrosis factor polymorphisms and acute rejection: proven link or provisional association? Transplantation 2000;69:1237-9.
18. Zegarska J, Paczek L, Mroz A, et al. Quantitative gene expression of TGF-β1, TNF-α, IL-1β and IL-6 in the renal artery wall of chronically rejected human renal allografts. Transplant Proc 2002;34:3176-9.
19. Li J, Grigoryev DN, Polotsky VY, et al. Chronic intermittent hypoxia upregulates genes of lipid biosynthesis in obese mice. J Appl Physiol 2005;99:1643-8.
20. Savransky V, Vivero A, Polotsky VY, et al. Chronic intermittent hypoxia predisposes to liver injury. Hepatology 2007;45:1007-13.
21. Nomiyama M, Ohnishi N, Yokoyama T, et al. Ticlopidine inhibits activation of mitogen-activated protein kinase by platelet-derived growth factor in cultured rat renal cells. Clin Exp Nephrol 1998;2:117-23.
22. Huwiler A, Stabel S, Pfeilschifter J, et al. Platelet-derived growth factor and angiotensin 2 stimulate the mitogen-activated protein kinase cascade in renal mesangial cells: comparison of hypertrophic and hyperplastic agonists. Biochem J 1995;305:777-84.
23. Chang CY, Argo CK, Caldwell SH, et al. Therapy of NAFLD: antioxidants and cytoprotective agents. J Clin Gastroenterol 2006;40:51-60.
24. Comar KM, Sterling RK. Review article: drug therapy for non-alcoholic fatty liver disease. Aliment Pharmacol Ther 2006;23:207-15.
25. Lin HZ, Yang SQ, Diehl AM, et al. Metformin reverses fatty liver disease in obese, leptin-daficient mice. Nat Med 2000;6:998-1003.
26. Lieber CS, Leo MA, DeCarli LM, et al. Acarbose attenuates experimental non-alcoholic steatohepatitis. Biochem Biophys Res Commun 2004;12:699-703.
27. Nagasawa T, Inada Y, Shibata N, et al. Effects of bezafibrate, PPAR pan-agonist, and GW501516, PPAR delta agonist, on development of steatohepatitis in mice fed a methionine-and choline-deficient diet. Eur J Pharmacol 2006;536:182-91.
28. Wanless IR, Belgiomo J, Huet PM. Hepatic sinusoidal fibrosis induced by cholesterol and stilbestrol in the rabbit: 1. Morphology and inhibition of fibrogenesis by dipyridamole. Hepatology 1996;24:855-64.
29. Murohara T, Horowitz JR, Isner JM, et al. Vascular endothelial growth factor/vascular permeability factor enhances vascular permeability via nitric oxide and prostacyclin. Circulation 1998;97:99-107.
30. Sánchez de Miguel L, de Frutos T, López-Farré A, et al. Aspirin inhibits inducible nitric oxide synthase expression and tumor necrosis factor-alpha release by cultured smooth muscle cells. Eur J Clin Invest 1999;29:93-9.
31. Campbell JS, Hughes SD, Fausto N, et al. Platelet-derived growth factor C induces liver fibrosis, steatosis, and hepatocellular carcinoma. Proc Natl Acad Sci USA 2005;102:3389-94.
32. Prattali RR, Barreiro GC, Carvalheira JB, et al. Aspirin inhibits serine phosphorylation of insulin receptor substrate 1 in growth hormone treated animals. FEBS Lett 2005;579:3152-8.
33. Matousovic K, Grande JP, Dousa TP, et al. Inhibitors of cyclic nucleotide phosphodiesterase isozymes type-3 and type-4 suppress mitogenesis of rat mesangial cells. J Clin Invest 1995;96:401-10.
34. Montminy M, Koo SH, Zhang X, et al. The CREB family: key regulators of hepatic metabolism. Ann Endocrinol 2004;65:73-5.
35. Klemm DJ, Roesler WJ, Reusch JE, et al. Insulin stimulates cAMP-response element binding protein activity in HepG2 and 3T3-L1 cell lines. J Biol Chem 1998;273:917-23.
36. Woo CW, Siow YL, O K, et al. Hyperhomocysteinemia induces hepatic cholesterol biosynthesis and lipid accumulation via activation of transcription factors. Am J Physiol Endocrinol Metab 2005;288: 1002-10.